Advertisements

Pregabalin Krka

Quick links to important sections

Pregabalin Krka

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Pregabalin Krka

Property Description
Active ingredient Pregabalin
Form Hard Capsule
Pharmacological class Anticonvulsant / Gabapentinoid
General purpose Calming hyper-sensitized nerves
Origin Synthetic

Pregabalin Krka is a synthetic, prescription-only medication supplied by the manufacturer Krka, containing the single active ingredient, Pregabalin, and is predominantly available as a hard capsule for oral administration. As a generic preparation, the product provides the same established therapeutic compound as its reference counterparts. Pregabalin is classified as a medicine that modulates nerve impulses.

Pregabalin's Pharmacological Class and Origin

The active substance, Pregabalin, belongs to the pharmacological class of anticonvulsants (antiepileptic drugs) and is specifically categorized as a gabapentinoid. This chemical entity is entirely synthetic in origin, having been created as a structural derivative of gamma-aminobutyric acid (GABA). Pregabalin is used for its ability to stabilize central nervous system activity.

How Pregabalin Works to Calm Hyper-Sensitized Nerves

Pregabalin works by binding with high affinity to the alpha-2-delta subunit of voltage-gated calcium channels found in the central nervous system. This specific mechanism distinguishes it from other sedatives.

By modulating this subunit, Pregabalin reduces the excessive release of excitatory neurotransmitters from nerve endings. This action results in a decrease in abnormal neuronal excitability, which is the key principle behind its general use scenario of calming hyper-sensitized nerve pathways in adults.

Regulatory References

  1. European Public Assessment Report (EPAR) for Lyrica
  2. EMA
Advertisements

What side effects are possible with Pregabalin Krka?

Possible side effects and safety information

Pregabalin Krka’s safety profile is documented based on official regulatory data, which classifies adverse reactions by frequency and affected body systems. These classifications are derived from clinical trial data and post-marketing surveillance.

Frequency-Classified Adverse Reactions

The most frequent effects are generally related to the Central Nervous System:

  • Very Common (>1/10): Dizziness and somnolence (drowsiness) are the most commonly reported reactions, often observed at the start of treatment.
  • Common (>1/100, <1/10): This category includes headache, peripheral oedema (swelling of limbs), weight gain, blurred vision, confusion, tremor, dry mouth, nausea, constipation, and fatigue. Some visual adverse reactions, such as blurred vision, may often resolve with continued treatment.

Serious Adverse Reactions and Systemic Risks

Regulatory documents highlight rare, but clinically significant, adverse reactions. These include Angioedema (swelling of the face, mouth, or throat) and severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS). Furthermore, the medicine is associated with a small, increased risk of suicidal ideation and behavior, a class effect noted for anti-epileptic drugs.

Population-Specific and Contextual Safety Notes

Safety statements exist for certain patient groups. Older adults may have an increased risk of falls due to common effects like dizziness. Patients with renal impairment require specific consideration, as the drug’s elimination is primarily via the kidneys. Cases of congestive heart failure have been reported post-marketing, mostly in elderly patients with pre-existing heart conditions.

Abrupt cessation of the medicine may lead to withdrawal symptoms (including insomnia, headache, and anxiety) and may increase the risk for seizures in patients with seizure disorders. The drug has a documented potential for abuse and dependence.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The information below outlines the officially documented manifestations of Pregabalin overexposure and the emergency actions mandated by regulatory authorities.


Overdose Scope

Property Description
Documented overdose presentations The most commonly reported events are Central Nervous System (CNS) effects, including somnolence (drowsiness), confusion, agitation, speech disorder (dysarthria), and ataxia (coordination loss). Severe overexposure has been associated with coma.
Physiological systems affected Central Nervous System and Respiratory System. Life-threatening respiratory depression is a documented risk.
Dose-related or exposure-related factors The risk of severe toxicity is significantly increased by co-ingestion with other CNS depressants, notably opioid pain medicines and alcohol.
Population-specific overdose notes Risk of serious respiratory depression is higher in elderly patients and those with underlying respiratory risk factors or compromised respiratory function.
Emergency-response statements No specific antidote is known. General supportive care and monitoring of vital signs are indicated. Unabsorbed drug may be eliminated via gastric lavage or emesis, and haemodialysis can effectively remove the drug from the plasma.
When immediate medical help is required Seek medical attention immediately for symptoms of serious breathing problems, including slowed/shallow breathing, extreme sleepiness or lethargy, unresponsiveness, or bluish-colored skin.

Connection to the overall overdose profile

Regulatory documents define the overdose profile by listing common CNS-related manifestations and explicitly identifying critical, life-threatening risks such as respiratory depression. This profile mandates that urgent medical attention must be sought when severe symptoms, particularly those involving breathing or responsiveness, are observed. The official guidance confirms the lack of a specific antidote and highlights supportive measures, including the use of haemodialysis in clinical management.

Advertisements

Therapeutic Uses of Pregabalin Krka

Quick Facts: Therapeutic Domains

  • May assist in managing nerve-related pain (neuropathic pain).
  • May contribute to seizure control when used alongside other treatments (adjunctive therapy).
  • May offer supportive care for Generalized Anxiety Disorder (GAD).

What Pregabalin Krka Treats: Main Uses and Benefits

Pregabalin Krka is a prescription medication that may be used to address several health conditions, primarily focusing on nervous system function and pain management. It is often prescribed for the management of peripheral and central neuropathic pain in adults. This type of pain is caused by damage to the nerves, and Pregabalin Krka may help in reducing the associated discomfort.

In the context of epilepsy, this medicine may be indicated for adults as adjunctive therapy to manage partial seizures with or without secondary generalization. This means it is typically added to other anti-epileptic drugs to assist in overall seizure control.

Furthermore, Pregabalin Krka may be utilized for the treatment of Generalized Anxiety Disorder (GAD) in adults. In this therapeutic domain, it may offer support in managing symptoms associated with GAD.

Advertisements

Eligibility and Restrictions for Use

Eligibility for Pregabalin Krka: Official Regulatory Information

Pregabalin Krka is licensed for use in adults (18 years and older). The regulatory profile defines clear constraints and absolute prohibitions for other populations.

Category Official Regulatory Status
Absolute Contraindication Hypersensitivity to pregabalin or any excipient.
Age-Related Rule Children and adolescents (under 18) are generally not recommended for treatment of most conditions (e.g., neuropathic pain, GAD) due to insufficient established data.
Renal Function Status Patients with renal impairment (reduced kidney function) are eligible, but the dose must be formally reduced based on creatinine clearance, as the drug is primarily eliminated by the kidneys.
Pregnancy Status Not recommended during pregnancy unless the benefit clearly outweighs the potential risk. Women of childbearing potential should use effective contraception.
Lactation Status Breastfeeding is not recommended during treatment.
Special Caution Group Patients with a history of substance abuse or dependence must be carefully assessed before prescription due to the risk of misuse.

These official statements establish the population boundaries for use as mandated by governmental health authorities.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacodynamic Interactions

Regulatory documents highlight a primary interaction risk through additive pharmacodynamic effects with other substances that depress the Central Nervous System (CNS). Co-administration with CNS depressants, including opioids and lorazepam, may increase the risk of severe reactions such as somnolence and respiratory depression.

Pharmacokinetic and Metabolic Profile

The medicine is eliminated primarily by renal excretion as unchanged drug; its clearance is directly proportional to creatinine clearance (CLcr). This defines the pharmacokinetic profile, indicating a potential for increased exposure with substances that reduce renal function. Official labeling confirms that Pregabalin is not substantially metabolized and does not inhibit or induce major Cytochrome P450 (CYP) liver enzymes, resulting in a low risk of metabolic interactions with most co-administered antiepileptic medicines or oral contraceptives.

Substance and Population-Specific Constraints

It is officially advised to avoid drinking alcohol (ethanol), as this may increase certain side effects of Pregabalin. In diabetic patients, co-administration with thiazolidinedione antidiabetic agents requires monitoring for peripheral edema. The elderly population is noted to be at a higher risk of severe respiratory depression when the medicine is combined with other CNS depressants.

Advertisements

Mechanism of Action

Targeted Modulation of the alpha2delta Subunit

Pregabalin works by binding with high affinity to the auxiliary alpha2delta (alpha-2-delta) subunit of presynaptic Voltage-Gated Calcium Channels (VGCCs) in the Central Nervous System (CNS). This specific interaction is a functional modulation that reduces the ability of these channels to insert into the nerve cell membrane, thereby decreasing calcium influx essential for transmitter release.

Functional Restriction of Excitatory Neurotransmitter Release

By limiting calcium influx, Pregabalin initiates a mechanistic cascade that significantly dampens the release of key excitatory neurotransmitters (such as glutamate and substance P) into the synapse. This process alters the fundamental chemical communication between nerves, which influences excessive signaling patterns.

Dampening of Neuronal Hyperexcitability

The resulting physiological effect of reduced neurotransmitter output is the dampening of neuronal hyperexcitability across pathways prone to overactivity in the CNS. This mechanism modulates signal traffic, contributing to an adjustment in activity across central nerve pathways.

Advertisements

Dosage and Administration Information

Pregabalin Krka hard capsules are strictly intended for oral administration and can be consumed independently of meals. The administration pattern requires the total daily dose to be divided into two or three separate doses to ensure consistent coverage throughout the day.

The protocol for initiating treatment involves a starting dose, generally 150 mg per day. Subsequent increases must be performed gradually, with dose titration occurring after intervals of 3 to 7 days based on patient response and tolerability, until the effective maintenance level is reached, not exceeding the maximum daily dose of 600 mg.

A mandatory procedural requirement is the adjustment of the daily dose in specific populations. For individuals with reduced kidney function, the dose must be reduced in accordance with their measured creatinine clearance. Those undergoing hemodialysis require a supplementary dose immediately following the procedure. Conversely, no dose adjustment is necessary for patients with hepatic impairment. When discontinuing the medicine, the established protocol mandates a gradual reduction over a minimum period of one week. If a dose is missed, patients should take only the next scheduled dose, strictly avoiding the doubling of the dose to compensate.

Advertisements

Recent Clinical Evidence

Pregabalin Krka: Recent Clinical Evidence

The following section summarizes the available research regarding Pregabalin, the active substance in Pregabalin Krka. These studies typically investigate the drug’s effects in conditions such as peripheral and central neuropathic pain, epilepsy (as adjunctive therapy for partial seizures), and Generalized Anxiety Disorder (GAD).


Research Focus (Early Studies)

The research focused on the properties of a selective alpha-2-delta (alpha2delta) subunit ligand. Early laboratory and animal model research explored whether this approach might affect key excitatory neurotransmitter release in the central nervous system, which is believed to be central to pain and seizure disorders.


Efficacy and Outcomes in Chronic Conditions

Clinical trials have investigated the potential of Pregabalin to affect outcomes across its approved indications. The primary measure in neuropathic pain studies is typically the change in the mean pain score on an 11-point numeric rating scale (NRS).

  • Neuropathic Pain: Studies involving painful diabetic peripheral neuropathy (PDPN) and postherpetic neuralgia (PHN) reported a reduction in mean pain scores compared to placebo. A significant proportion of participants in these trials achieved a ge30% reduction in pain intensity.
  • Epilepsy and GAD: Research in patients with partial-onset seizures reported a reduction in seizure frequency when Pregabalin was added to existing treatment. In trials concerning GAD, the drug was associated with a reduction in anxiety symptoms measured by standard rating scales.

Safety and Tolerability Profile

The safety profile was reported across all clinical phases, focusing on adverse event rates and laboratory abnormalities.

  • Common Adverse Events (AEs): Common AEs included reports of dizziness and somnolence. These effects are typically dose-dependent and were the most frequent reasons for discontinuation in some studies.
  • Clinical Monitoring: Studies recorded that participants underwent monitoring of renal function, as the elimination of Pregabalin is closely linked to creatinine clearance. Tolerability was assessed in most study participants, and research examined the tolerability profile in participants with compromised renal function.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Pregabalin Krka (FAQ)

Q: Is Pregabalin Krka the same as Lyrica?

Pregabalin Krka is described as a generic version of the originator brand. This means that both products contain the same active ingredient, pregabalin. According to official documents, generic preparations provide the same established therapeutic compound as their reference counterparts.

Q: How quickly does Pregabalin Krka typically start working for nerve pain?

Based on initial clinical observations, some patients may begin to notice an effect on pain relief within the first week of starting treatment. However, the exact time it takes to experience the intended effect can vary among individuals.

Q: What kind of medications should not be taken with Pregabalin Krka?

Regulatory documents advise caution when combining this medicine with substances that also depress the central nervous system (CNS), which is the brain and spinal cord. Such CNS depressants include opioid pain relievers or certain anti-anxiety medications. Combining them may lead to increased risks of side effects such as severe sleepiness or breathing difficulties.

Q: Is Pregabalin Krka safe for older adults?

Official regulatory guidance notes that older adults should be treated with caution. This population may be at an increased risk of falls due to common effects like dizziness and sleepiness. Furthermore, when combined with other CNS depressants, there is a heightened risk of severe breathing issues.

Q: Does Pregabalin Krka interact with common over-the-counter painkillers?

Because the medicine is primarily eliminated by the kidneys as unchanged drug, the risk of metabolic interactions with many other medicines is low. However, some over-the-counter (OTC) painkillers may contain ingredients that cause drowsiness. If an OTC medicine slows brain activity, combining it with pregabalin may increase common side effects like sleepiness.

Q: Is it safe to take Pregabalin Krka if I am already on anti-depressants?

Official information does not highlight a major metabolic interaction between pregabalin and most common anti-depressant medicines. However, taking both could potentially increase sedative effects, such as sleepiness or dizziness. The coordination of treatment involving anti-depressants is managed by your healthcare provider.

Q: How does the medicine know whether to treat pain or seizures?

Pregabalin works by modulating nerve signals in the central nervous system. Its core action is dampening the excessive signaling, or hyperexcitability, that is believed to underlie conditions like chronic nerve pain and seizure disorders. This single mechanism, the stabilization of overactive nerve pathways, influences multiple medical conditions.

Q: Do studies support the use of Pregabalin Krka for long-term conditions?

Yes, the medicine is approved for use in chronic conditions, such as certain types of nerve pain and Generalized Anxiety Disorder (GAD). Clinical trials have evaluated efficacy and safety, including studies that lasted up to 12 weeks. Further long-term safety information continues to be collected through official post-marketing surveillance.

Q: Does Pregabalin Krka affect my ability to drive or operate machinery?

Official product information advises that this medicine can cause side effects like dizziness and somnolence (sleepiness). These effects may impair your ability to perform tasks that require focus, such as driving or operating machinery. Caution is advised until you are aware of how the medicine affects your mental and physical capabilities.

Q: What is the difference between pregabalin and gabapentin?

Both medicines are classified as gabapentinoids and share a similar mechanism for modulating nerve impulses. However, they differ in how the body processes them, known as their pharmacokinetic properties. For instance, studies show pregabalin is absorbed more quickly and predictably compared to gabapentin.

Q: Are there any specific foods or drinks to avoid while on this medication?

Official guidance strongly advises patients to avoid consuming alcohol while taking this medicine. Alcohol may increase certain side effects of pregabalin. Regarding food, the medicine can be taken either with or without meals, as the presence of food does not significantly affect its absorption.

Q: What is the evidence for using Pregabalin Krka for fibromyalgia?

In some regulatory jurisdictions, such as the United States, pregabalin is an approved treatment for fibromyalgia in adults. Clinical studies have been conducted to evaluate and support the medicine’s efficacy for this specific condition.

Q: Does Pregabalin Krka show up on drug tests?

Pregabalin is legally classified as a controlled substance in many jurisdictions, such as a Schedule V drug in the United States. While it is not typically included in standard drug screening panels, it can be detected if a specific test for pregabalin is performed, particularly if monitoring for misuse is necessary.

Q: Does Pregabalin Krka interact with herbal supplements like St. John's Wort?

Caution is advised regarding the use of pregabalin with certain herbal products like St. John's Wort. Official information indicates that combining these substances could increase side effects, including dizziness, confusion, and drowsiness.

Q: If I am allergic to other medicines, can I still take Pregabalin Krka?

The medicine carries an absolute contraindication for anyone with a known hypersensitivity (severe allergic reaction) to pregabalin itself or any of its inactive components. The suitability of this medicine requires assessment by a healthcare professional, including a review of any existing allergies to other medicines.

Q: Is it necessary to have blood tests while taking Pregabalin Krka?

Official documents note that pregabalin is primarily eliminated by the kidneys, and its clearance is monitored via kidney function (creatinine clearance). While regular monitoring of kidney function may require blood tests for some patients, the need for routine blood tests during treatment is a decision made by your prescribing doctor.

Q: Can Pregabalin Krka be taken with certain antacids?

Regulatory guidance suggests that certain antacid medicines may potentially interfere with the absorption of pregabalin. Official instructions outline a specific time interval that should separate the intake of antacids and this medicine.

Q: Can a patient develop a tolerance to Pregabalin Krka over time?

Regulatory guidance advises that patients be monitored for signs of potential misuse, abuse, or dependence. This monitoring includes checking for the development of tolerance, which is the need to take increasing amounts of the medicine to achieve the same effect.

Q: Are there any known interactions between Pregabalin Krka and common cold/flu remedies?

Many common cold and flu remedies contain ingredients that can slow down brain activity, such as sedating antihistamines or alcohol. Because pregabalin also acts as a CNS depressant, combining it with these remedies may lead to increased side effects like dizziness, confusion, and excessive sleepiness.

Q: What happens if I take too much Pregabalin Krka?

Official information on overdose suggests that effects may include severe sleepiness (somnolence), agitation, restlessness, or confusion. In very rare cases, an overdose has been associated with coma. In cases where an overdose is suspected, urgent medical attention should be sought.

Q: Is Pregabalin Krka a controlled substance?

Yes, pregabalin is designated as a controlled substance in several countries, such as a Schedule V medicine in the United States. This classification indicates that the medicine has a recognized potential for abuse or dependence, although this potential is generally considered low relative to other controlled substances.

Q: Are there specific symptoms that mean I should contact a healthcare professional immediately while taking Pregabalin Krka?

Official regulatory information strongly advises immediate medical attention for symptoms suggesting a serious allergic reaction, such as swelling of the face, lips, tongue, or throat (Angioedema). The development of severe blistering or peeling of the skin (such as Stevens-Johnson syndrome or SJS) is considered a medical emergency requiring immediate attention.

Q: Does Pregabalin Krka affect sleep patterns other than causing sleepiness?

Beyond the common side effect of somnolence (sleepiness), studies indicate that pregabalin can affect the structure of sleep. Evidence suggests it may increase the proportion of deep, slow-wave sleep while potentially reducing the number of times a person wakes up during the night.

Q: Are the side effects of Pregabalin Krka permanent?

Most side effects are described as generally reversible and usually resolve upon dose adjustment or discontinuation of the medicine. Official reports have specifically noted the resolution of certain visual side effects and cases of renal failure after the medicine was stopped.

Q: What conditions must be managed before starting Pregabalin Krka?

Caution is officially recommended for patients with a history of substance misuse, as well as those with pre-existing conditions affecting the heart or kidneys. Official guidance notes that these conditions may require special assessment, management, and monitoring by a doctor before treatment with pregabalin begins.

Q: Can men experience specific side effects while taking Pregabalin Krka?

Most side effects reported for pregabalin are not specific to gender. However, regulatory post-marketing data indicates that rare, specific adverse events have been reported in males, including breast enlargement (gynecomastia) and inflammation of the epididymis.

Advertisements

How should Pregabalin Krka be stored and disposed of?

How to Store and Dispose of Pregabalin Krka?

Official regulatory guidelines mandate specific storage and disposal requirements for pregabalin hard capsules to maintain product integrity and ensure public safety.


Storage Requirements

Pregabalin must be stored at Controlled Room Temperature, which is between 20 C to 25 C (68 F to 77 F). The product should not be stored above 30 C and must be kept in its original container with the lid tightly closed to protect it from moisture. Mandatory child-safety rules require the medication to be stored out of the sight and reach of children.


Disposal Instructions

Unused or expired Pregabalin Krka must not be thrown away via household waste or flushed down the toilet, as this may harm the environment. Disposal must be carried out in accordance with local or national pharmaceutical regulations. This often involves returning the unneeded medication to a pharmacy or a designated collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pregabalin Krka found in:

A-Z Index: